Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 780 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene expression study Clear all
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

NCT01336933
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
Interventions
prednisone, cyclophosphamide, etoposide, Vincristine, pralatrexate, laboratory biomarker analysis, comparative genomic hybridization, gene expression analysis, nucleic acid sequencing, mutation analysis, immunohistochemistry staining method, microarray analysis, RNA analysis
Drug · Other · Genetic
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Stanford, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 22, 2026, 2:56 PM EDT
Recruiting Phase 2 Interventional

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT04606914
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
Interventions
mirvetuximab soravtansine (MIRV; IMGN853)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06162572
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE, S095029 RDE, Cemiplimab
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Detroit, Michigan • Canton, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Active, not recruiting No phase listed Observational

MElanoma Research Lymph Node Prediction Implementation National_001

NCT04759781
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
SkylineDx
Industry
Eligibility
18 Years and older
Enrollment
1,820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Completed No phase listed Observational

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

NCT01521039
View directory record Official record
Conditions
Acute Graft-versus-Host Disease, Allogeneic Stem Cell Transplant
Interventions
Blood samples
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 22, 2026, 2:56 PM EDT
Terminated Phase 2 Interventional Results available

Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

NCT00723203
View directory record Official record
Conditions
Leukemia
Interventions
panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 22, 2026, 2:56 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia

NCT01010256
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 22, 2026, 2:56 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bereavement Support Program for Caregivers

NCT05826145
View directory record Official record
Conditions
Bereavement
Interventions
Vocal Expression, Cognitive Behavioral
Behavioral
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 22, 2026, 2:56 PM EDT
Completed No phase listed Observational

Study of Blood Samples From Newborns With Down Syndrome

NCT00959283
View directory record Official record
Conditions
Myeloid Proliferations Associated With Down Syndrome
Interventions
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 90 Days
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
173
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 130 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 22, 2026, 2:56 PM EDT
Completed Not applicable Interventional

vEAET for Older Veterans With Chronic Musculoskeletal Pain Pilot

NCT04552860
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Emotional Awareness and Expression Therapy
Behavioral
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
60 Years to 95 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 22, 2026, 2:56 PM EDT
Completed No phase listed Observational

Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia

NCT01146223
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Childhood Acute Promyelocytic Leukemia (M3)
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 22, 2026, 2:56 PM EDT
Completed No phase listed Observational

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

NCT03788746
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
58
States / cities
Little Rock, Arkansas • Glendale, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 22, 2026, 2:56 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988
View directory record Official record
Conditions
Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
Interventions
Mirvetuximab Soravtansine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Sarasota, Florida • Edgewood, Kentucky • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

NCT04477928
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Sera and whole blood sampling, Differential Gene Expression (DGE)
Diagnostic Test
Lead sponsor
Sanford Health
Other
Eligibility
0 Minutes to 17 Years
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2031
U.S. locations
4
States / cities
Bemidji, Minnesota • Bismarck, North Dakota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Not listed No phase listed Observational

Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia

NCT00898092
View directory record Official record
Conditions
Leukemia
Interventions
microarray analysis, molecular genetic technique, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years to 59 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 22, 2026, 2:56 PM EDT
Completed No phase listed Observational

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

NCT01414595
View directory record Official record
Conditions
Lung Cancer
Interventions
DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
11
States / cities
Los Angeles, California • Lewes, Delaware • Newark, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 22, 2026, 2:56 PM EDT
Completed Phase 1 Interventional

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

NCT03790670
View directory record Official record
Conditions
Parkinson Disease
Interventions
sargramostim
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 22, 2026, 2:56 PM EDT
Suspended Phase 1Phase 2 Interventional

RGX-111 Gene Therapy in Patients With MPS I

NCT03580083
View directory record Official record
Conditions
Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome, Hurler-Scheie Syndrome
Interventions
RGX-111
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
4 Months and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Recruiting Not applicable Interventional

Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma

NCT05989230
View directory record Official record
Conditions
Orthopaedic Trauma, Chronic Pain, Musculoskeletal Injury
Interventions
Emotional Awareness and Expression Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Recruiting Not applicable Interventional

Shockwave in Postoperative Breast Reconstruction Fibrosis

NCT06919042
View directory record Official record
Conditions
Fibrosis Breast
Interventions
Pulsed Acoustic Cellular Expression therapy
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Conscious Pregnancy: Supporting Maternal Cardiometabolic Health With Mindfulness

NCT06898658
View directory record Official record
Conditions
Maternal Cardiometabolic Health, Molecular Impact of Psychological Stress and Socioeconomic Adversity, Maternal Inflammatory Markers, Maternal Diabetes, Maternal Behavior, Maternal Distress
Interventions
Mindfulness Intervention
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 22, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

NCT01396070
View directory record Official record
Conditions
Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome
Interventions
Brentuximab vedotin
Drug
Lead sponsor
Youn Kim
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 22, 2026, 2:56 PM EDT
Completed Phase 1 Interventional

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

NCT00873275
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
Biological · Drug · Genetic + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 22, 2026, 2:56 PM EDT
Terminated No phase listed Observational Results available

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

NCT01567722
View directory record Official record
Conditions
Lung Cancer, Lymphoma
Interventions
DNA analysis, RNA analysis, gene expression analysis, polymorphism analysis, biologic sample preservation procedure, flow cytometry, medical chart review
Genetic · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 22, 2026, 2:56 PM EDT